Related Experiment Video
Updated: May 21, 2025

External Cephalic Version: Is it an Effective and Safe Procedure?
Published on: June 6, 2020
Cabergoline Use and Pregnancy Outcomes: A Systematic Review
Anne-Sophie Otis1,2, Marie-Sophie Brochet1,2,3, Zoë Tremblay1,2
1Department of Pharmacy, CHU Sainte-Justine, Montreal, Quebec, Canada.
Introduction:
Lack of available expert guidelines leads clinicians to interrupt cabergoline treatment upon confirmation of pregnancy and consider switching to bromocriptine, which is more commonly used during pregnancy but is poorly tolerated.
Objective:
The objective of this review was to evaluate pregnancy outcomes, primarily major malformations and spontaneous abortions, after pregnancy exposure to cabergoline during the first trimester compared to pregnancy exposure to other comparators or no treatment.
Methods:
An Embase, Pubmed, Google Scholar, and ClinicalTrials.gov search was performed. Full articles published before October 27, 2022, and evaluating the effect of cabergoline on major malformations and spontaneous abortions were considered for inclusion in the review. Search results were manually screened and selected by two independent reviewers.
Results:
Totally, 2186 records were identified. After removal of duplicates and screening of abstracts, 65 full-text articles were consulted. Thirty articles corresponded to our selection criteria and were included in the systematic review. This review identified 1662 pregnancies exposed to cabergoline. Most studies did not find an increased risk of congenital malformations or spontaneous abortions with cabergoline compared to other comparators or no treatment. Overall study quality was low, and there was high heterogeneity between studies.
Conclusion:
This review revealed no negative impact on major malformations and spontaneous abortions of cabergoline use in pregnancy compared to other comparators or no treatment. However, additional high-quality studies are needed to further study the safety of cabergoline use during pregnancy.
Trial Registration:
PROSPERO, CRD42021256219 (October 19, 2021).
More Related Videos
05:36Author Spotlight: Inducing Pseudopregnancy in Female Mice Without the Need for Vasectomized Males Prior to Non-Surgical Embryo Transfer or Artificial Insemination
Published on: July 7, 2023
06:24Fertility Sparing Procedure using Carbon Dioxide Fiber Laser Vaporization of Ovarian Endometrioma
Published on: July 6, 2022
Related Concept Videos
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Birth Control Methods
Teratogenicity